How has Xofigo shutdown affected you?
Its day 19 since Xofigo production stopped. Malecare continues to dig deep, trying to learn when production might start up again. Meanwhile, How are you? Please email Joel at joel@malecare.org about how the Xofigo shutdown [...]
Lack of PSA Decline as an Independent Predictor of Biochemical Failure Post Salvage Radiation Therapy
It would be of great advantage to us if we were able to improve the early detection of responders to salvage external beam radiotherapy (RT) after failed radical prostatectomy (RP). Early detection would allow us [...]
An Increase in the Risk of Second Primary Cancers in Men with Prostate Cancer: A Population-Based Cohort Study
The good news for us is that the survival of men diagnosed with prostate cancer has improved over time. The current 10-year relative survival rate is 99.7%! However, the long survival of men who have [...]
Why You Must Get Provenge Now
A recent announcement stated that Dendreon’s immunotherapy Provenge (sipuleucel-T) is too expensive to be used as a treatment for advanced prostate cancer under the National Health Service in England. In preliminary draft guidelines out this [...]
Xofigo Patients Face Uncertainty About Their Health
Men currently being treated with Xofigo should ask their doctors, today, “What should I do in light of the current shortage of Xofigo?” In our October 8, 2014 bog post, we cited data from the [...]
Xofigo distribution temporarily suspended because of a recently discovered manufacturing problem
The world wide supply of Xofigo (radium Ra-223 dichloride) available for patients will run out on October 10, 2014. Xofigo is the newly FDA approved treatment for men with castrate resistant metastatic prostate cancer (CRPC) [...]